Table 2.

Proportion of participants with virological suppression (HIV-1 RNA <50 copies per mL)

		Supplemental dolutegravir arm (n=53)	Placebo arm (n=55)
Week 24*
	Modified intention to treat	43/52 (83%, 70–92)	44/53 (83%, 70–92)
	Per protocol	43/51 (84%, 71–93)	44/52 (85%, 72–93)
Week 12†
	Modified intention to treat	42/53 (79%, 66–89)	46/55 (84%, 71–92)
	Per protocol	42/53 (79%, 66–89)	46/54 (85%, 73–93)
Week 48†
	Modified intention to treat	34/49 (69%, 55–82)	35/52 (67%, 53–80)
	Per protocol	34/47 (72%, 57–84)	35/46 (76%, 61–87)

Data are n/N (%, 95% CI).

^*Primary endpoint.

^†Secondary endpoint.